Guideline for the diagnosis and management of myelofibrosis

John T Reilly, Mary Frances McMullin, Philip A Beer, Nauman Butt, Eibhlean Conneally, Andrew Duncombe, Anthony R Green, N George Michaeel, Marie H Gilleece, Georgina W Hall, Steven Knapper, Adam Mead, Ruben A Mesa, Mallika Sekhar, Bridget Wilkins, Claire N Harrison, Writing group: British Committee for Standards in Haematology

Research output: Contribution to journalArticlepeer-review

81 Citations (Scopus)


The guideline group regarding the diagnosis and management of myelofibrosis was selected to be representative of UK-based medical experts, together with a contribution from a single expert from the USA. MEDLINE and EMBASE were searched systematically for publications in English from 1966 until August 2011 using a variety of key words. The writing group produced the draft guideline, which was subsequently revised by consensus of the members of the General Haematology and Haemato-oncology Task Forces of the British Committee for Standards in Haematology (BCSH). The guideline was then reviewed by a sounding board of UK haematologists, the BCSH and the British Society for Haematology Committee and comments incorporated where appropriate. The criteria used to state levels and grades of evidence are as outlined in the Procedure for Guidelines commissioned by the BCSH; the 'GRADE' system was used to score strength and quality of evidence. The objective of this guideline is to provide healthcare professionals with clear guidance on the investigation and management of primary myelofibrosis, as well as post-polycythaemic myelofibrosis (post-PV MF) and post-thrombocythemic myelofibrosis (post-ET MF) in both adult and paediatric patients.
Original languageEnglish
Pages (from-to)453-71
Number of pages19
JournalBritish Journal of Haematology
Issue number4
Publication statusPublished - Aug 2012

Bibliographical note

© 2012 Blackwell Publishing Ltd.

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Guideline for the diagnosis and management of myelofibrosis'. Together they form a unique fingerprint.

Cite this